Pipeline Preview

News
Article

Muraglitazar (Pargluva, Bristol-Myers Squibb, Merck) for the treatment of type 2 diabetes.

Approvable designations

Fast-track designations

Orphan drug designations

Non-approvable designations

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.